Products for Research Use Only
RegisterLogin

SCR7

CAT: 0804-HY-12742-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12742-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SCR7 is an unstable form that can be autocyclized into a stable form SCR7 pyrazine. SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces cell apoptosis and has anticancer activity[1][2].
CAS Number
1533426-72-0
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Apoptosis; CRISPR/Cas9; DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/SCR7.html
Purity
98.22
Solubility
DMSO : ≥ 45 mg/mL
Smiles
O=C(N1)C(/N=C/C2=CC=CC=C2)=C(NC1=S)/N=C/C3=CC=CC=C3
Molecular Formula
C18H14N4OS
Molecular Weight
334.39
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Srivastava M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012 Dec 21;151 (7) :1474-87.|[2]Lin C, et al. Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells. Sci Rep. 2016 Oct 7;6:34531.|[3]Supriya V Vartak, et al. Autocyclized and Oxidized Forms of SCR7 Induce Cancer Cell Death by Inhibiting Nonhomologous DNA End Joining in a Ligase IV Dependent Manner. FEBS J. 2018 Nov;285 (21) :3959-3976.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
BMC Biotechnol. 2021 Jul 27;21 (1) :45.|Cell Death Discov. 2025 Aug 23;11 (1) :402.|EMBO Rep. 2019 Mar;20 (3) :e46821.|J Genet Genomics. 2021 Feb 20;48 (2) :134-146.|J Immunol. 2020 Apr 1;204 (7) :1904-1918.|J Immunother Cancer. 2022 Jan;10 (1) :e003809.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Mol Ther Nucleic Acids. 2024 Jul 17;35 (3) :102274.|Onco Targets Ther. 2018 Aug 17:11:4945-4953.|Sens Actuators B Chem. 19 February 2022, 131598.|Stem Cell Res Ther. 2024 Dec 2;15 (1) :458.|Viruses. 2023 Nov 14;15 (11) :2256.|Int J Mol Sci. 2022 Jul 7;23 (14) :7518.|Int J Mol Sci. 2025 May 3;26 (9) :4361.|Nat Commun. 2025 Jul 15;16 (1) :6502.|Sci Adv. 2025 Jul 11;11 (28) :eadw1720.|Trends Biotechnol. 2025 Aug 30:S0167-7799 (25) 00314-2.|Trends Biotechnol. 2025 Jul;43 (7) :1743-1764.|University of Georgia. 2025.|Virology. 2025 May:606:110504.

Related Products

CatalogName
HY-18711A-01SCR-1481B1
HY-169257-01SCR-7952
HY-170958Scr-IN-1
HY-100458SCR-4026
HY-175845Scr-IN-2
HY-18711-01SCR-1481B1 (free base)

Alternative Products

CatalogName
406600SCR7
C4941-10SCR7 pyrazine

Popular Products